With a market cap of $53.9 billion, Edwards Lifesciences Corporation (EW) is a global leader in structural heart innovation, dedicated to improving patient lives through breakthrough medical technologies and evidence-based solutions. Driven by a patient-focused culture and strong partnerships with clinicians and healthcare stakeholders, the company delivers life-changing innovations to people around the world.
Shares of the Irvine, California-based company have slightly underperformed the broader market over the past 52 weeks. EW stock has increased 19.8% over this time frame, while the broader S&P 500 Index ($SPX) has gained 19.9%. Moreover, shares of the company have risen 9.9% on a YTD basis, compared to SPX's 12.9% return.
